Recombinant Guinea Pig Asparaginase His-tag Protein, CF

Recombinant Guinea Pig ASPG His-tag (Catalog # 10238-AS) is measured by its ability to convert asparagine to aspartic acid.

2 μg/lane of Recombinant Guinea Pig Asparaginase His-tag was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing a band under reducing conditions at 57 kDa.

• Reactivity: Gp
• Applications: Enzyme Activity
• Format: Carrier-Free

Recombinant Guinea Pig Asparaginase His-tag Protein, CF Summary

• Details of Functionality: Measured by its ability to convert asparagine to aspartic acid. The specific activity is >2700 pmol/min/μg, as measured under the described conditions.
• Source: E. coli-derived guinea pig Asparaginase protein
  Ala2-Ile565
  with an N-terminal Met and 6-His tag
• Accession #: XP_003463186
• N-terminal Sequence: Met
• Protein/Peptide Type: Recombinant Enzymes
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Enzyme Activity
• Theoretical MW: 62 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 57 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.
• Buffer: Supplied as a 0.2 μm filtered solution in Tris, NaCl and TCEP.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Assay Procedure:
  • Assay Buffer: 25 mM Tris, pH 7.5
  • Recombinant Guinea Pig Asparaginase His-tag (rgpASPG) (Catalog # 10238-AS)
  • Substrate: L-Asparagine (Sigma, Catalog # A0884), 100 mM stock in Assay Buffer
  • alpha -Ketoglutaric Acid (Sigma, Catalog # K2010), 1 M stock in deionized water
  • beta -Nicotinamide adenine dinucleotide, reduced disodium salt hydrate (NADH) (Sigma, Catalog #
  • N8129), 20 mM stock in 0.1 M Sodium Borate, pH 9.0
  • Glutamic-Oxalacetic Transaminase (Sigma, Catalog # G2751)
  • Malic Dehydrogenase (Sigma, Catalog # M2634)
  • 96-well Clear Plate (Catalog # DY990)
  • Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent
  1. Prepare a Reaction Mixture containing 800 µM NADH, 800 µM alpha -Ketoglutaric Acid, 8 Unit/mL Glutamic-Oxalacetic Transaminase and 4 unit/mL Malic Dehydrogenase in Assay Buffer.
  2. Dilute L-Asparagine to 20 mM in Assay Buffer.
  3. Dilute rgpASPG to 8 ng/µL in Assay Buffer.
  4. Load in plate, 25 µL of 8 ng/µL rgpASPG and add 25 µL of Reaction Mixture to all wells. Include a Substrate Blank containing 25 µL Assay Buffer and 25 µL of Reaction Mixture.
  5. Start the reaction by adding 50 µL of 20 mM L-Asparagine to all wells.
  6. Read plate in kinetic mode for 5 minutes at an absorbance of 340 nm.
  7. Calculate specific activity:

  Specific Activity (pmol/min/µg) = (Adjusted Vmax* (OD/min) x well volume (L) x 10^12 pmol/mol x -1) / (ext. coeff** (M^-1cm^-1) x path corr.*** (cm) x amount of enzyme (µg))

  
  *Adjusted for Substrate Blank
  **Using the extinction coefficient 6220 M^-1cm^-1
  ***Using the path correction 0.32 cm
  Note: the output of many spectrophotometers is in mOD Per Well:
  • rgpASPG: 0.2 µg
  • L-Asparagine: 10 mM
  • NADH: 200 µM
  • alpha -Ketoglutaric Acid: 200 µM
  • Glutamic-Oxalacetic Transaminase: 2 Units
  • Malic Dehydrogenase: 1 Unit

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Guinea Pig Asparaginase His-tag Protein, CF

• AnsA
• AnsB
• Asparaginase
• ASPG
• C14orf76
• Colaspase
• Cytoplasmic asparaginase I
• L ASNase I
• L ASNase II
• L asparaginase 1
• L asparaginase 2
• L asparaginase I
• L asparaginase II precursor
• L asparaginase II
• L asparagine amidohydrolase I
• L asparagine amidohydrolase II

Background

L-Asparaginases catalyze the conversion of L-asparagine (Asn) to L-aspartic acid (Asp) and play important roles in amino acid metabolism of significance in medical, antimicrobial, and food industry applications (1). Guinea pig ASPG (gpASPG), also known as ASNase1, is a tetramer composed of a dimer of dimers. Each protomer contains a N-terminal domain with the active site and a C-terminal domain that can act as a lid when substrate is bound (2). gpASPG was identified as an L-asparaginase capable of inhibiting tumor growth (3, 4). It was observed that unlike most normal cells, in acute lymphatic leukemia (ALL) there is little or no detectable asparagine synthetase making cancer cells specifically sensitive to extracellular asparagine depletion with asparaginase treatment (5-7). Although bacterial asparaginases are currently available as therapeutics in ALL (8), treatment using bacterial origin asparaginase leads to immunogenic intolerance and clearance issues from the blood (9). Additionally, the bacterial asparaginases also show an unnecessary side L-glutaminase activity (10). For these reasons, a human-like enzyme would be preferred for therapeutic use (9, 11) but must have efficient hydrolysis of extracellular Asn with a Km value in the low micromolar range (2). Human ASPG is unable to match the required efficiency for therapeutic use (2, 12, 13), but gpASPG is homologous and has similar kinetic efficiency to the bacterial enzymes currently being used as therapeutics (2, 14). gpASPG may consequently make an appropriate mammalian-source therapeutic for replacement. There is significant focus on asparaginases given the broad beneficial applications for these enzymes.

1. Vimal, A. and A. Kumar (2017) Biotechnol. Genet. Eng. Rev. 33:40.
2. Schalk, A. M. et al. (2014) J. Biol. Chem. 289:33175.
3. Kidd, J. G. (1953) J. Exp. Med. 98:565.
4. Broome, J. D. (1963) J. Exp. Med. 118:99.
5. Neuman, R. E. and T. A. McCoy (1956) Science 124:124.
6. Haley, E. E. et al. (1961) Cancer Res. 21:532.
7. Su, N. et al. (2008) Pediatr. Blood Cancer. 50:274.
8. Salzer, W. L. et al. (2014) Ann. N.Y. Acad. Sci. 1329:81.
9. Muller, H. J. and J. Boos (1998) Crit. Rev. Oncol. Hematol. 28:97.
10. Chan, W. K. et al. (2014) Blood 123:3596.
11. Dellinger, C. T. and T. D. Miale (1976) Cancer 38:1843.
12. Belviso, S. et al. (2017) PLoS One. 12:e0178174.
13. Karamitros, C. S. and M. Konrad (2014) J. Biol. Chem. 289:12962.
14. Srikhanta, Y. N. et al. (2013) Biochem. Biophys. Res. Commun. 436:362.

Bioinformatics

• Uniprot:
  • XP_003463186()